Smith Salley & Associates trimmed its holdings in shares of Clorox Co (NYSE:CLX) by 6.8% during the third quarter, HoldingsChannel.com reports. The firm owned 12,554 shares of the company’s stock after selling 919 shares during the quarter. Smith Salley & Associates’ holdings in Clorox were worth $1,888,000 as of its most recent filing with the SEC.
Several other large investors have also modified their holdings of the business. Parnassus Investments CA raised its holdings in shares of Clorox by 1.6% during the second quarter. Parnassus Investments CA now owns 4,711,970 shares of the company’s stock worth $637,294,000 after purchasing an additional 76,149 shares during the period. Macquarie Group Ltd. raised its holdings in shares of Clorox by 437,400.0% during the second quarter. Macquarie Group Ltd. now owns 1,750,000 shares of the company’s stock worth $236,688,000 after purchasing an additional 1,749,600 shares during the period. Schroder Investment Management Group raised its holdings in shares of Clorox by 57.0% during the second quarter. Schroder Investment Management Group now owns 1,506,358 shares of the company’s stock worth $201,641,000 after purchasing an additional 547,070 shares during the period. Morgan Stanley raised its holdings in shares of Clorox by 44.2% during the second quarter. Morgan Stanley now owns 1,101,380 shares of the company’s stock worth $148,962,000 after purchasing an additional 337,621 shares during the period. Finally, Swiss National Bank raised its holdings in shares of Clorox by 1.9% during the second quarter. Swiss National Bank now owns 955,992 shares of the company’s stock worth $129,298,000 after purchasing an additional 17,600 shares during the period. 78.35% of the stock is currently owned by institutional investors.
A number of analysts recently weighed in on CLX shares. BMO Capital Markets increased their price objective on shares of Clorox from $153.00 to $165.00 and gave the stock a “buy” rating in a report on Friday, November 2nd. Citigroup increased their price objective on shares of Clorox from $149.00 to $153.00 and gave the stock a “neutral” rating in a report on Friday, November 2nd. Barclays set a $138.00 price objective on shares of Clorox and gave the stock a “hold” rating in a report on Thursday, November 1st. Wells Fargo & Co reaffirmed a “hold” rating on shares of Clorox in a report on Wednesday, October 31st. Finally, ValuEngine raised shares of Clorox from a “hold” rating to a “buy” rating in a report on Saturday, September 22nd. Four equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and four have assigned a buy rating to the stock. The company has an average rating of “Hold” and an average price target of $141.64.
Clorox (NYSE:CLX) last released its quarterly earnings data on Wednesday, October 31st. The company reported $1.62 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.59 by $0.03. The business had revenue of $1.56 billion for the quarter, compared to analysts’ expectations of $1.53 billion. Clorox had a net margin of 13.59% and a return on equity of 102.65%. The company’s revenue for the quarter was up 4.2% compared to the same quarter last year. During the same quarter last year, the company earned $1.46 EPS. As a group, research analysts forecast that Clorox Co will post 6.31 earnings per share for the current fiscal year.
The business also recently announced a quarterly dividend, which will be paid on Friday, November 16th. Shareholders of record on Wednesday, October 31st will be paid a dividend of $0.96 per share. The ex-dividend date is Tuesday, October 30th. This represents a $3.84 annualized dividend and a yield of 2.42%. Clorox’s payout ratio is 61.34%.
In other Clorox news, SVP Diego J. Barral sold 12,880 shares of the firm’s stock in a transaction dated Tuesday, November 6th. The shares were sold at an average price of $157.98, for a total transaction of $2,034,782.40. Following the transaction, the senior vice president now owns 18,603 shares of the company’s stock, valued at approximately $2,938,901.94. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, SVP Michael R. Costello sold 9,265 shares of the firm’s stock in a transaction dated Monday, August 13th. The shares were sold at an average price of $140.02, for a total transaction of $1,297,285.30. Following the transaction, the senior vice president now directly owns 34,293 shares in the company, valued at approximately $4,801,705.86. The disclosure for this sale can be found here. In the last three months, insiders have sold 96,353 shares of company stock worth $14,762,793. 1.40% of the stock is owned by corporate insiders.
TRADEMARK VIOLATION WARNING: “Smith Salley & Associates Reduces Holdings in Clorox Co (CLX)” was published by Community Financial News and is the property of of Community Financial News. If you are accessing this report on another publication, it was illegally copied and reposted in violation of U.S. & international copyright & trademark laws. The original version of this report can be read at https://www.com-unik.info/2018/11/10/smith-salley-associates-reduces-holdings-in-clorox-co-clx.html.
The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Cleaning, Household, Lifestyle, and International. The company offers laundry additives, including bleach products under the Clorox brand, as well as Clorox 2 stain fighter and color booster; home care products primarily under the Clorox, Formula 409, Liquid-Plumr, Pine-Sol, S.O.S, and Tilex brands; naturally derived products under the Green Works brand; and professional cleaning, disinfecting, and food service products under the Clorox, Dispatch, HealthLink, Clorox Healthcare, Hidden Valley, KC Masterpiece, and Soy Vay brands.
Want to see what other hedge funds are holding CLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Clorox Co (NYSE:CLX).
Receive News & Ratings for Clorox Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clorox and related companies with MarketBeat.com's FREE daily email newsletter.